Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-Takayasu arteritis
CTR20230110Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Takayasu arteritis (TAK) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: Time from baseline to first Takayasu arteritis relapse. Started Sep 2023; status: active.
02
Drugs
upadacitinib
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on CTR20230110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230110.